Durable response by olaparib for a Japanese patient with primary peritoneal cancer with multiple brain metastases: A case report

We report the case of a 58‐year‐old Japanese woman with recurrent PPC with multiple BM. After obtaining informed consent from the patient, we performed BRCA tes ting that detected a deleterious BRCA 1 mutation. At that time, olaparib was not yet approved in Japan, we learned about the compassionate use program of olaparib called Managed Access Program (MAP). Of note, we have established a system to enroll patients in MAP. After olaparib treatment, the patie nt exhibited a considerable decrease of BMs. Eighteen months since the initiation of olaparib treatment, the patient has reported no evidence of disease progression. Olaparib maintenance treatment could be effective for Japanese patients with PPC and multiple BMs.
Source: Journal of Obstetrics and Gynaecology Research - Category: OBGYN Authors: Tags: Case Report Source Type: research